Previous 10 | Next 10 |
CytomX Therapeutics (CTMX +16.2%) rose following its FY21 results, which missed on analysts' estimates. Q4 total revenues rose 20.2% Y/Y to $19.7M. The increase in Q4 revenue was largely related to the CD71 collaboration with AbbVie. FY21 revenue declined to $69.57M, compared to $100.36M...
Gainers: Organogenesis (NASDAQ:ORGO) +24%. CytomX Therapeutics (NASDAQ:CTMX) +13%. X4 Pharmaceuticals (NASDAQ:XFOR) +13%. MannKind (NASDAQ:MNKD) +10%. Allied Healthcare (NASDAQ:AHPI) +6%. Losers: Karyopharm Therapeutics (NASDAQ:KPTI) -31%. Bright Health Grou...
Image source: The Motley Fool. CytomX Therapeutics (NASDAQ: CTMX) Q4 2021 Earnings Call Mar 01, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Q4 2021 Earnings Conference Call March 1, 2022 17:00 ET Company Participants Chau Cheng - Vice President of Investor Relations & Corporate Communications Sean McCarthy - Chairman & Chief Executive Officer Amy Peterson - President & Chief Operating ...
CytomX press release (NASDAQ:CTMX): FY GAAP EPS of -$1.30 misses by $0.13. Revenue of $69.57M (-30.7% Y/Y) misses by $5.85M. For further details see: CytomX GAAP EPS of -$1.30 misses by $0.13, revenue of $69.57M misses by $5.85M
- Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 - - First-in-human study of CX-904 in advanced solid tumors to be initiated in first half of 2022 - - Initial data for Arms A and B in Phase 2 ...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a virt...
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 1, ...
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced the promotion of Amy C. Peterson, M.D., to the position of president and chief operating officer, ...
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug ...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...